On 8 January SandRidge Energy, Inc. (NYSE:SD) announced financial results for the quarter that ended September 30, 2014. The Company also filed restated results for quarterly periods in 2013 and 2014. Adjusted EBITDA, pro forma for divestitures and net of Non controlling Interest, was $225 million in the third quarter of 2014 compared to $160 million in the third quarter of 2013, 41% year-over-year growth. On Friday shares of SandRidge Energy, Inc. (NYSE:SD) closed at $1.22. Company’s sales growth for last 5 years was 10.90% and EPS growth for next 5 years is recorded as 30.90%.
On 14 January Hertz Global Holdings, Inc. (NYSE:HTZ) said that it has added Thomas Sabatino, a former Walgreens Boots Alliance executive, to its leadership team. Hertz Global Holdings, Inc. (NYSE:HTZ) in last trading activity decreased -0.14% to close at $21.28. Company weekly performance is -9.22% while its quarterly performance stands at 2.06%. Hertz Global Holdings, Inc. (NYSE:HTZ) is -32.68% away from its 52 week high.
ARCA biopharma, Inc. (NASDAQ:ABIO) major shareholder Riley Mccormack sold 550,000 shares of Arca Biopharma stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $0.92, for a total value of $506,000.00. On last trading day ARCA biopharma, Inc. (NASDAQ:ABIO) increased 0.16% to close at $0.77. Its volatility for the week is 6.33% while volatility for the month is 7.67%. ABIO’s EPS growth for past 5 years was 63.20%. ARCA biopharma, Inc. (NASDAQ:ABIO) monthly performance is -17.96%.
On 13 January Acorn Energy, Inc. (NASDAQ:ACFN) announced that it received a letter from the Nasdaq Listings Qualification Staff stating that the Company is not in compliance with the continued listing requirements of The Nasdaq Global Market because the bid price of the Company’s common stock has closed below the minimum$1.00 per share requirement of Listing Rule 5450(a)(1) for 30 consecutive business days. Acorn Energy, Inc. (NASDAQ:ACFN) has 1.40% insider ownership while its institutional ownership stands at 13.40%. In last trading activity company’s stock closed at $0.59.
Zacks lowered shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) from an outperform rating to a neutral rating in a research report released on Tuesday morning. Zacks currently has $7.70 price objective on the stock. On last trading day Ocera Therapeutics, Inc. (NASDAQ:OCRX) increased 2.45% to close at $6.27. Its volatility for the week is 8.30% while volatility for the month is 7.42%. OCRX’s EPS growth for past 5 years was 25.60%. Ocera Therapeutics, Inc. (NASDAQ:OCRX) monthly performance is 9.81%.